Michael Mingueneau

Company: Sail Biomedicines

Job title: Head of Immunology

Seminars:

In Vivo Reversible Programming of T cells with SAIL’s Targeted NP-eRNA Platform for Treatment of Autoimmune Diseases & Beyond 1:30 pm

• Enabling in vivo reversible programming of T cells with SAIL’s targeted LNP-eRNA technology platform • Replacing a complex, costly, and genome-integrative cell therapy product with an off-the-shelf, and non-integrative IV injectable product by encoding a CAR specific for hCD19 directly in the patient’s T cells in vivo • Advancing a first-generation in situ CAR…Read more

day: Conference Day Two